Centene Corporation (CNC)
What changed in recent filings
- Revenue +10% YoYQuarter ended Jun 30, 2026
- Medicare segment 13% → 21%Sep 30, 2024 → Jun 30, 2026
- Institutions — 3 added · 6 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Centene Corporation recent earnings releases
Based on SEC filings. The release date is the day the earnings filing (8-K) was accepted; for quarters where that filing was not found, the periodic report filing date is shown.
- 26Q2Released Jul 28, 2026Revenue +9.9% YoY · EPS $2.19Released after the close: Jul 27 close → Jul 28 close, the stock moved -0.3% · over the same window, market +0.2% · sector +2.4%
- 26Q1Released Apr 28, 2026Revenue +7.1% YoY · EPS $3.11Released after the close: Apr 27 close → Apr 28 close, the stock moved +14.0% · over the same window, market -0.5% · sector -0.5%
- 25Q4Released Feb 6, 2026Revenue +21.9% YoY · EPS $-2.24Released after the close: Feb 5 close → Feb 6 close, the stock moved -3.7% · over the same window, market +1.9% · sector +1.8%
- 25Q3Released Oct 29, 2025Revenue +18.2% YoY · EPS $-13.50Released after the close: Oct 28 close → Oct 29 close, the stock moved +12.5% · over the same window, market +0.0% · sector -1.1%
The next earnings release is estimated around Oct 28, 2026 (calculated from how long this company has taken between quarter end and filing; it is not a date announced by the company).
Institutions holding Centene Corporation
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 8 → 2026 Q2: 9 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Centene Corporation
Institutions we track that reported holding this stock in their most recent 13F.
- National Pension Service (Korea)0.04% of portfolio · held as of 2019 Q1 or earlier
- Capital World Investors0.01% of portfolio · held as of 2020 Q3 or earlier
- Bridgewater Associates0.10% of portfolio · since 2022 Q1
- Harris Associates (Oakmark)0.95% of portfolio · since 2023 Q3
- Greenlight Capital2.71% of portfolio · since 2024 Q4
- Glenview Capital Management2.20% of portfolio · since 2025 Q3
- Tudor Investment Corp0.02% of portfolio · since 2025 Q4
- Caisse de depot (Quebec)0.13% of portfolio · since 2026 Q1
- Point72 Asset Management0.05% of portfolio · since 2026 Q1
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Q2 2026 13F recap — stocks several institutions bought and sold together →Company overview
Centene Corp. is a managed healthcare company that provides health coverage and related services across the United States. The company focuses on government-sponsored and commercial health programs, with core operations in Medicaid, Medicare, and the Health Insurance Marketplace. It serves individuals, families, and communities through locally branded health plans and a network of regional teams designed to deliver coordinated care. Centene also offers Medicare Prescription Drug Plans, long-term services and supports, and other health solutions that address the needs of underinsured and vulnerable populations. Its business model centers on affordable access to care, combining insurance products with administrative and care management services. Headquartered in St. Louis, Missouri, Centene plays a significant role in the U.S. managed care market, particularly in programs serving public health and individual coverage needs.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Centene Corporation is classified under the Biotech & Health sector. See peers below.
Centene Corporation key financials
Based on SEC filings · as of Jun 30, 2026
Tap a metric name to see its meaning in the glossary.
Centene Corporation vs Biotech & Health sector benchmark
Median of 38 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
CNC revenue by segment summary
SEC 10-Q · segment totals cross-checked against total revenue
2026-06-30 revenue was $53.6B, +9.9% YoY.
The largest segment is Medicaid, 59.7% of revenue — a concentrated structure.
Recent revenue growth was led mainly by the Medicaid segment (about 82% of the increase).
Full segment weights, YoY changes, and an AI synthesis are available in the detailed analysis.
CNC segment revenue mix trend
Quarterly change in segment revenue share · verified from SEC filings
ETFs holding Centene Corporation
Per SEC N-PORT · 2026-06-30 · by weight · factual
CNC on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
CNC FAQ
What is Centene Corporation (CNC)?
Centene Corp. is a managed healthcare company that provides health coverage and related services across the United States. The company focuses on government-sponsored and commercial health programs, with core operations in Medicaid, Medicare, and the Health Insurance Marketplace. It serves individuals, families, and communities through locally branded health plans and a network of regional teams designed to deliver coordinated care. Centene also offers Medicare Prescription Drug Plans, long-term services and supports, and other health solutions that address the needs of underinsured and vulnerable populations. Its business model centers on affordable access to care, combining insurance products with administrative and care management services. Headquartered in St. Louis, Missouri, Centene plays a significant role in the U.S. managed care market, particularly in programs serving public health and individual coverage needs.
What sector is Centene Corporation in?
Centene Corporation is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Centene Corporation's key financials?
As of Jun 30, 2026 in SEC filings: Revenue growth (YoY) 13.9%, Operating margin 2.2%, Net margin -2.5%, ROE -33.4%, Debt-to-equity 0.71x. Definitions and interpretation are available on Stocklore.
What are Centene Corporation's main revenue segments?
The largest segment is Medicaid, about 59.7% of revenue. Segment totals are cross-checked against total revenue from SEC filings.
Where can I analyze Centene Corporation (CNC) stock?
On Stocklore you can see CNC's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.